Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

NCT02716272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma

Interventions

DRUG: Nivolumab
DRUG: Nivolumab + Ipilimumab

Sponsor

Intergroupe Francophone de Cancerologie Thoracique